The increase in MITF levels, especially in PTX monotherapy and combination groups, was accompanied by macroscopic evidence of enhanced pigmentation in the tumors, suggesting a shift towards a more differentiated melanoma phenotype. The gene discussed is MITF; the disease is melanoma.